Business Context and Reporting Period
Company: ResMed Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2003
Business Overview: ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with manufacturing facilities in Australia, Germany, and the United States, selling products in over 60 countries.
Key Financial Metrics (Fiscal Year 2003)
| Metric | Value (in thousands) |
|---|---|
| Net Revenues | $273,570 |
| Gross Profit | $173,087 |
| Gross Margin | 63.3% |
| Net Income | $45,729 |
| Diluted Earnings Per Share | $1.33 |
| Operating Cash Flow | $59,284 |
| Long-Term Debt (Convertible Notes) | $113,250 |
| Working Capital | $191,322 |
| Cash and Cash Equivalents | $114,491 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 34% to $273.6 million from $204.1 million in 2002. Growth was driven by increased unit sales, the inclusion of Servo Magnetics Inc. (SMI) operations, and favorable foreign currency exchange rates.
- Profitability: Net income rose 22% to $45.7 million. However, gross margin decreased from 65% to 63% due to higher manufacturing costs from a stronger Australian dollar and lower-margin motor sales from the SMI acquisition.
- Acquisitions: The company acquired John Stark and Associates in July 2002. The SMI acquisition (May 2002) contributed $6.5 million in revenue and $2.6 million in SG&A expenses.
- Debt Reduction: The company repurchased $10.0 million face value of convertible subordinated notes, reducing outstanding debt to $113.25 million.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management emphasizes continued product innovation (e.g., AutoSet Spirit, Magellan), geographic expansion, and increasing public/clinical awareness of SDB. R&D spending increased to $20.5 million (7.5% of revenue).
- Capital Projects: Construction is underway on a new 215,000 sq. ft. manufacturing facility in Sydney, Australia, expected to be completed in the first half of calendar 2004.
- Legal Proceedings: Significant patent litigation with Respironics and Fisher & Paykel Healthcare was settled during the fiscal year. All claims were dismissed with prejudice.
- Risk Factors:
- Reimbursement: Reliance on third-party payers (Medicare, private insurers) creates risk if reimbursement rates decline or coverage is denied.
- Competition: Highly competitive market with larger rivals (Respironics, DeVilbiss, Nellcor Puritan Bennett).
- Foreign Exchange: Significant exposure to currency fluctuations, particularly the Australian dollar, which impacts manufacturing costs and reported earnings.
- Regulatory: Subject to strict FDA and international regulations; delays in approvals could hinder new product launches.
Investor Verification Checklist
- Reimbursement Trends: Verify current reimbursement policies in key markets (US, Europe, Australia) for CPAP and VPAP devices.
- Currency Hedging: Review the effectiveness of the company's foreign currency hedging program against the Australian dollar and Euro.
- Acquisition Integration: Assess the financial performance and integration status of recent acquisitions (SMI, MAP, Labhardt).
- Patent Portfolio: Confirm the status of key patents and the resolution of any remaining intellectual property disputes.
- Capital Expenditures: Monitor the progress and cost of the new Sydney manufacturing facility.